The weight-loss drug boom that began as a U.S. phenomenon is rapidly becoming a global growth story. Investors have spent much of the past year obsessing over American prescriptions, especially the launch of GLP-1 pills that could broaden access to obesity treatments. But the bigger opportunity may be unfolding overseas, where demand for these medicines is accelerating. Novo Nordisk’s international obesity-drug sales rose 44% in the first quarter of 2026, compared with 9% gro
